BioTuesdays

Tag - SRRA

Sierra Oncology

HCW starts Sierra Oncology at buy; PT $20

H.C. Wainwright launched coverage of Sierra Oncology (NASDAQ:SRRA) with a “buy” rating and $20 price target. The stock closed at $12.46 on July 29. Sierra Oncology is in the midst of a Phase 3 MOMENTUM study with its...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.